Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma

Published:2019-03-16 Issue:4 Volume:36 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Ishihara Hiroki^ORCID,Takagi Toshio,Kondo Tsunenori,Tachibana Hidekazu,Fukuda Hironori,Yoshida Kazuhiko,Iizuka Junpei,Kobayashi Hirohito,Okumi Masayoshi,Ishida Hideki,Tanabe Kazunari

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-019-1261-5.pdf

Reference22 articles.

1. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. https://doi.org/10.1056/NEJMoa1510665 .

2. Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90. https://doi.org/10.1056/NEJMoa1712126 .

3. George S, Rini BI, Hammers HJ. Emerging role of combination immunotherapy in the first-line treatment of advanced renal cell carcinoma: a review. JAMA Oncol. 2018. https://doi.org/10.1001/jamaoncol.2018.4604 .

4. De Giorgi U, Carteni G, Giannarelli D, Basso U, Galli L, Cortesi E, et al. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU Int. 2018. https://doi.org/10.1111/bju.14461 .

5. Zahoor H, Barata PC, Jia X, Martin A, Allman KD, Wood LS, et al. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. J Immunother Cancer. 2018;6(1):107. https://doi.org/10.1186/s40425-018-0425-8 .

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up;Japanese Journal of Clinical Oncology;2022-04-03

2. Clinical Implications of HSC70 Expression in Clear Cell Renal Cell Carcinoma;International Journal of Medical Sciences;2021

3. Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients;Cancers;2020-11-18

4. Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma;Targeted Oncology;2019-07-29